$26.20−0.77 (−2.85%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Vera Therapeutics (VERA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+378.1%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼96.9%
−299.6
FY21→FY25CAGR —
Free cash flow ($M)▼78.2%
−241.7
FY21→FY25CAGR —
Diluted EPS▼69.5%
−4.66
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+378.1%
13.4mn → 64.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$630.0K
−35.2% YoY in FY25.
Returns vs FCF
n/m
$0.0M returned vs $−241.7M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 10,277.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | 3,296.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 6,981.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 246,654.0 | 215,256.0 | 126,172.0 | 78,225.0 | 68,993.0 | 22,484.0 | ▲70.6% | +75.9% |
Selling, general & admin | 187,857.0 | 100,217.0 | 40,998.0 | 23,787.0 | 21,910.0 | 11,918.0 | ▲144.4% | +70.3% |
Total operating expenses | 434,511.0 | 315,473.0 | 167,170.0 | 102,012.0 | 90,903.0 | 34,402.0 | ▲88.7% | +74.0% |
Operating incomefeeds ROC rank | −427,530.0 | −315,473.0 | −167,170.0 | −102,012.0 | −90,903.0 | −34,402.0 | ▼88.7% | — |
Other income, net | 12,218.0 | 15,859.0 | 15,023.0 | 6,023.0 | 1,848.0 | 1,794.0 | — | — |
Pretax income | −415,312.0 | −299,614.0 | −152,147.0 | −95,989.0 | −89,055.0 | −32,608.0 | ▼96.9% | — |
Income tax | — | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | ▲0.0% | +0.0% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −415,313.0 | −299,615.0 | −152,148.0 | −95,990.0 | −89,056.0 | −32,609.0 | ▼96.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −5.90 | −4.66 | −2.75 | −2.25 | −3.35 | −2.43 | ▼69.5% | — |
Diluted shares (mn) | 72.13 | 64.23 | 55.33 | 42.71 | 26.57 | 13.44 | ▲16.1% | +47.9% |
| Margins | ||||||||
Gross margin | 67.9% | — | — | — | — | — | — | — |
Operating margin | −4160.1% | — | — | — | — | — | — | — |
Net margin | −4041.2% | — | — | — | — | — | — | — |
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

